Physiologically based pharmacokinetics and cancer risk assessment

Area of Science:

• Toxicology
• Pharmacokinetics
• Computational Biology

Background:

• Physiologically based pharmacokinetic (PBPK) modeling mathematically describes chemical disposition.
• This approach divides the body into biologically relevant, anatomically accurate tissue compartments.
• PBPK models integrate quantitative data on chemical disposition determinants within a biological framework.

Purpose of the Study:

• To demonstrate the application of PBPK models in predicting tissue dosimetry of toxic moieties.
• To evaluate the accuracy of PBPK models in risk assessment for chemicals like dichloromethane.
• To compare PBPK model-based risk assessment with conventional methods.

Main Methods:

• Developing PBPK models by defining physiological characteristics of tissue compartments.
• Integrating physicochemical and biological data for chemical disposition.
• Applying PBPK models to predict tissue dosimetry and extrapolate dose-response relationships.

Main Results:

• PBPK models enable extrapolation of pharmacokinetic behavior across doses, routes, and species.
• A PBPK model for dichloromethane predicted a significantly lower cancer risk in humans compared to conventional methods.
• The PBPK approach estimated a human cancer risk of 3.7 x 10(-8) for lifetime inhalation exposure to 1 µg/m³.

Conclusions:

• PBPK modeling offers a robust framework for predicting target tissue exposure to toxic chemicals in humans.
• This approach significantly reduces uncertainty in risk assessment compared to traditional methods.
• PBPK models are valuable tools for enhancing the accuracy and reliability of chemical risk assessments.